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Background: Graphic warning labels are a tobacco control best practice that is mandated in the US for
cigarettes under the 2009 Family Smoking Prevention and Tobacco Control Act. However, smokeless tobacco
products are not required to carry graphic warning labels, and as of September 2014, electronic cigarettes in
the US carry no warning labels and are aggressively marketed, including with “reduced harm” or “FDA
Approved” messages.
Methods: In this online experiment, 483 US adult non-users of tobacco were randomized to view print advertisements
for moist snuff, snus, and e-cigarettes with either warning labels (current warning label, graphic warning label) or
“endorsements” (a “lower risk” label proposed by a tobacco company, an “FDA Approved” label) or control (tobacco
advertisement with no label, advertisement for a non-tobacco consumer products). Main outcome measures included
changes in perceived harm, positive attitudes towards, openness to using, and interest in a free sample of moist snuff,
snus, and e-cigarettes.
Results: The graphic warning label increased perceived harm of moist snuff and e-cigarettes. “Lower risk”
and “FDA Approved” labels decreased perceived harm of moist snuff and snus respectively. Current warning
label and graphic warning label significantly lowered positive attitudes towards e-cigarettes. In this
sample of non-users of tobacco, 15% were interested in a free sample of alternative tobacco products
(predominantly e-cigarettes). Proportion of participants interested in a free sample did not differ significantly
across the conditions, but those interested in a free sample had significantly lower perceptions of harm of
corresponding tobacco products.
Conclusions: Regulatory agencies should not allow “lower risk” warning labels, which have similar effects
to the “FDA Approved” label, which is prohibited, and should consider implementing graphic warning
labels for smokeless tobacco products and e-cigarettes.
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Tobacco use remains the leading cause of preventable
death in the United States [1]. Risks of tobacco use have
been identified [2], and understanding of these risks is
one of the main factors that explains initiation and ces-
sation of tobacco use [3-7].
One of the central approaches to increasing perceived
risk of tobacco products has been the use of warning* Correspondence: lyudmila.popova@ucsf.edu
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article, unless otherwise stated.labels [8]. Most research to date has focused on cigarette
warning labels, specifically graphic warning labels, which
have been mandated by law in 63 countries globally [9].
Graphic warning labels promote cessation behavior [10,11]
and are effective in communicating the harm of cigarettes
[8]. In the US, in 2009 the Family Smoking Prevention and
Tobacco Control Act mandated the Food and Drug Ad-
ministration (FDA) to implement graphic warning labels
on cigarettes, bringing the US closer in alignment to the
World Health Organization’s Framework Convention on
Tobacco Control (FCTC) [12] and the European Commis-
sion’s Tobacco Product Directive [13], both of whichntral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
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US graphic warning labels would cover top 50% of both
front and back of cigarette packages, which is consistent
with WHO FCTC recommendation of 50% or more of the
principal display areas [12], but is less than the recently re-
vised European Commission’s Tobacco Product Directive
(65% of the front and back of the cigarette pack) [13].
In addition, new warning labels may be developed for
tobacco products other than cigarettes. In recent years,
tobacco and e-cigarette companies have been aggres-
sively developing and promoting new alternative tobacco
products, such as electronic cigarettes (e-cigarettes), snus,
and dissolvable tobacco products [14-17]. E-cigarettes are
electronic devices generally consisting of a battery con-
nected to a heater, a mouthpiece, and a chamber contain-
ing a solution of propylene glycol and other chemicals,
frequently including nicotine. When the device is used,
the solution is vaporized by the heater, producing an aero-
sol that is inhaled. Snus is ground tobacco placed in a
porous pouch to be placed between lip and gum to
allow nicotine absorption; snus sold in the US is mod-
eled after a traditional Swedish product which typically
is manufactured so that it contains fewer tobacco-
specific nitrosamines (carcinogens) than other forms of
chewing tobacco [18].
Currently, some of these products (smokeless tobacco)
carry warning labels, and others (e-cigarettes) do not.
While graphic warning labels have been mandated by
law for cigarettes, they have not been established for al-
ternative tobacco products, and research on the effects
of graphic warning labels on smokeless tobacco is nas-
cent [19]. There is no research on the effects of warning
labels on e-cigarettes, and the current marketing fre-
quently refers to reduced risk. A systematic content ana-
lysis of electronic cigarette websites found 95% of websites
made health related claims, such as the statement, “Can’t
argue with 4,000 less chemicals!” [20]. While it has been
suggested that e-cigarettes should be promoted as “re-
duced harm” alternatives to combustible cigarettes for
smokers [21], there are no long term data on the health ef-
fects of e-cigarette use, and widespread promotion may
also result in uptake among non-users of tobacco, which
would be inconsistent with harm reduction on a popula-
tion level [22]. Warning labels on e-cigarettes might dis-
courage people who do not use tobacco from starting. We
investigated the effects of placing warning labels on e-
cigarette advertising on perceived harm of e-cigarettes
among non-users, hypothesizing that any warning label
will increase perceptions of harm of e-cigarettes.
Since 1998, marketing expenditures for smokeless to-
bacco have increased by 277% [23]. Since 2009, cigarette
companies have purchased smokeless tobacco compan-
ies, and now sell both traditional and novel smokeless
tobacco products, which are frequently promoted fortemporary use in smoke-free environments [14]. In the
United States, smokeless tobacco products (moist snuff,
snus, dissolvables) currently display one of four text warn-
ing labels mandated for smokeless tobacco products:
“WARNING: This product can cause mouth cancer.”
“WARNING: This product can cause gum disease and
tooth loss.”
“WARNING: This product is not a safe alternative to
cigarettes.”
“WARNING: Smokeless tobacco is addictive.”
In 2011, R. J. Reynolds Tobacco Company submitted a
Citizen Petition to the US Food and Drug Administra-
tion requesting to change one of the smokeless tobacco
warning labels from “WARNING: This product is not a
safe alternative to cigarettes” to “WARNING: No to-
bacco product is safe, but this product presents substan-
tially lower risks to health than cigarettes” [24], linking
the warning statement to an implicit endorsement.
In addition, there have been longstanding concerns
that tobacco companies might try to use FDA regulation
(and their compliance with it) as a marketing strategy
and promote new tobacco products as meeting the FDA
requirements or being “FDA Approved”. Although the
Family Smoking Prevention and Tobacco Control Act ex-
plicitly prohibits use of “FDA Approved” language for mar-
keting of tobacco products, this restriction currently does
not apply to e-cigarettes, which are sometimes advertised
as “made in an FDA Approved facility” [25-28]. The
“endorsement” label proposed by R. J. Reynolds may
also be interpreted like an “FDA Approved” label.
To our knowledge, there are currently no studies on
the effect of communicating FDA oversight of tobacco
on consumer perceptions of harm of new tobacco prod-
ucts. The R. J. Reynolds’ proposed “endorsement” label
has not been studied empirically, and it might act equiva-
lently to an “FDA Approved” endorsement. This study
compared the label proposed by R. J. Reynolds to a label
stating the product is “FDA Approved”. We hypothesized
that exposure to either of the reduced harm messages
would decrease perceived harm of alternative tobacco
products, and that the R. J. Reynolds label would have an
effect similar to the “FDA Approved” label.
Methods
Participants
Participants were 506 non-users of tobacco recruited by
Toluna (www.toluna-group.com), a survey and market
research company, to complete a single online experi-
ment. Participants were recruited through a variety of
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to surveys in exchange for cash rewards provided by
Toluna. The sample was screened to include only adults
aged 18+ who were not established tobacco users, (e.g., they
had not smoked 100 cigarettes in their entire life, and had
not used smokeless tobacco such as chewing tobacco, snuff,
dip, or snus at least 20 times in their entire life). Participants
who reported current (past 30 day) use of any alternative to-
bacco products (n = 23) were excluded from further analyses
in order to focus on non-users of tobacco. Thus, the final
sample included 483 non-users of tobacco. Among them,
4% had ever tried one of the new and alternative tobacco
products, but not in the past month.
To ensure eligibility of participants, participants had to
enter their zip code in the beginning and end of the survey;
those whose zip codes did not match had their session ter-
minated. Additional procedures for data quality control are
described at http://www.toluna-group.com/about-toluna/
about/data-quality-approach. All participants completed
electronic informed consent forms and all protocols were
approved by the Committee on Human Research (the IRB)
at the University of California San Francisco.Pretest Moist snuff
ad



























Figure 1 Study design and experimental procedure.Procedure
The experimental procedure is illustrated in Figure 1.
Participants began by filling out a pretest questionnaire
comprising demographic questions, measures of past to-
bacco use and outcome variables (perceived harm, posi-
tive attitudes, and openness to using moist snuff, snus,
and e-cigarettes). They were then randomized to one of
six groups: five groups saw advertisements for alternative
tobacco products with either a warning: 1) current warn-
ing label, “Warning: This product is not a safe alterna-
tive to cigarettes” (this warning is currently mandated
for smokeless tobacco), 2) graphic warning label (picture
of a mouth sore and words “Warning: This product can
cause mouth cancer;” an endorsement: 3) R. J. Reynolds’s
proposed “lower risk” label, “Warning: No tobacco prod-
uct is safe, but this product presents substantially lower
risks to health than cigarettes,” 4) “FDA Approved” label;
5) an advertisement for a tobacco product with no warn-
ing label, or 6) a control group that saw advertisements
for a non-tobacco consumer products (such as a cell
phone or gum) (Figure 1). While the “FDA Approved”
label is prohibited for tobacco products currently regulateds ad
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son to the prohibited message. In each experimental condi-
tion, participants saw advertisements for three products
(presented in random order to mitigate order effects):
moist snuff, snus, and e-cigarettes. For each product, the
advertisement shown was randomly drawn from three ad-
vertisements for each type of alternative tobacco products.
Warning labels were added to the bottom of each adver-
tisement to cover 20% of the total area of the advertise-
ment as required by law for smokeless tobacco warnings
[29]. Following exposure to each advertisement, partici-
pants completed outcome measures (perceived harm, atti-
tudes, and intentions to use this product) in a posttest.
Median time to complete the study was 12 minutes.
Measures
Demographics and tobacco use
Demographic variables included sex, age, race, annual
household income, educational level, and geographical
region. Ever and current (past 30 days) use of alternative
tobacco products was measured for each of five alterna-
tive tobacco products: loose leaf, moist snuff, snus, dis-
solvables, and electronic cigarettes.
Outcome variables
Perceived harm of tobacco products was measured with
two questions: ‘In your opinion, how harmful is …
(moist snuff, snus, e-cigarettes) to general health?’ and
‘In your opinion, to what extent does … cause cancer?’ re-
ported on 9-point Likert scales ranging from ‘Not at all’ to
‘Extremely.’ The answers to the two questions were averaged
to create a perceived harm scale (Cronbach’s alphas 0.95-
0.98) for each of the three products. The positive attitudes
scales comprised four items measured on a 9-point semantic
differential scales: “Using (moist snuff, snus, e-cigarettes) is:
good-bad, intelligent-unintelligent, appropriate-not appro-
priate, and pleasant-unpleasant” with higher scores indicat-
ing more positive attitudes (Cronbach’s alphas 0.96-0.98).
The answers to four questions were averaged. Openness to
trying each of the alternative tobacco products was mea-
sured with one item, “How open are you to trying … (moist
snuff, snus, e-cigarettes) in the future?” with answers
on 9-point Likert scales ranging from ‘Not at all open’
to ‘Extremely open’.
Behavioral task - selection of free sample of alternative
tobacco products
After the exposure to each advertisement, participants
were offered a free sample of alternative tobacco prod-
ucts and asked to select the brand and flavor. After see-
ing a moist snuff advertisement, participants could choose
among Copenhagen, Grizzly, or Skoal moist snuff. After
seeing a snus advertisement, participants could choose
among Camel snus, Marlboro snus, and General snus,and after seeing an e-cigarette advertisement, they could
choose among blu, V2, or NJOY e-cigarette. In every case,
they could also select “Not interested in a free sample” op-
tion. In the end of the study, the participants were in-
formed that no samples would actually be mailed to them
and that this study did not endorse or promote tobacco
use in any way. This behavioral selection task has been
used in prior studies [30,31].
All products in the same experimental condition bore
the same warning label. In the end, participants were
asked to select which warning label they saw on the ad-
vertisements, with choices being “No warning labels”,
the text for the four labels (warnings and endorsements)
used in the study, and two additional smokeless tobacco
warning labels.Statistical analyses
All analyses were conducted in IBM SPSS version 21. To
examine the effects of individual warning labels on changes
in perceived harm we used general linear models (GLM)
with time as within-subject factor and warning label condi-
tion as between-subject factor. Interactions between time
and condition were examined to determine whether any
significant omnibus differences over time by condition
were present. In addition, we explored pre-post differences
within each condition in order to determine which condi-
tions exhibited the strongest differences between the
pretest and posttest measurements. Multiple paired
comparisons of cell means featured p-value adjustment
via Tukey’s honestly significant difference (HSD) pro-
cedure to maintain a nominal alpha of .05.Results
Description of the sample
The national sample of 483 non-users of tobacco was
44.1% male, mean age was 47 years. There were no sig-
nificant differences in participant characteristics between
experimental conditions (Table 1). Levels of outcome
variables (perceived harm, attitudes, and openness to
using moist snuff, snus, and e-cigarettes) measured at
pretest are presented in Table 2.
There were no significant differences on the levels of
outcome variables at pretest based on gender, age, edu-
cation, income, and geographical region, with the follow-
ing exceptions. Women perceived e-cigarettes as more
harmful than men did (5.2 vs. 4.5, t(450) = 2.60, p < .05).
Among age groups, 18–29 year olds were significantly
more open to trying e-cigarettes in the future than
those 60 years old or older (1.66 vs. 1.08, F(3, 468) =
4.02, p < .01). In terms of geographical region, partici-
pants from the West perceived e-cigarettes as signifi-
cantly more harmful than did participants from the
Northeast (5.57 vs. 4.17, F(3, 476) = 4.23, p < .01).
Table 1 Participant demographic characteristics for the total sample and for each (randomly assigned) experimental
group
Characteristic N % No warning
label (n = 75),%
Current warning












Male 206 44.1 45.0 38.5 39.2 48.8 50.0 42.5
Female 249 55.9 55.0 61.5 60.8 51.2 50.0 57.5
Age, years
18-29 70 17.2 13.8 16.7 15.2 22.6 15.9 18.8
30-44 127 27.3 31.3 32.1 27.8 20.2 29.3 23.8
45-59 134 28.8 28.7 19.2 32.9 27.4 26.8 37.5
60+ 124 26.7 26.3 32.1 24.1 29.8 28.0 20.0
Race
White 232 53.0 55.0 46.2 57.0 57.1 53.7 48.8
Black or African American 94 20.1 13.8 25.6 24.1 14.3 20.7 22.5
American Indian or Alaska
Native
12 2.7 3.8 3.8 2.5 2.4 1.2 2.5
Asian 91 18.6 23.8 16.7 12.7 19.0 19.5 20.0
Native Hawaiian or Pacific
Islander
3 0.8 0.0 2.6 0.0 1.2 1.2 0.0
Multiple Races 21 4.3 2.5 5.1 3.8 6.0 3.7 5.0
Unknown 2 0.4 1.3 0.0 0.0 0.0 0.0 1.3
Education
High school or less 81 19.7 15.0 20.5 21.5 16.7 20.7 23.8
Some college 91 21.9 22.5 20.5 21.5 25.0 24.4 17.5
Bachelor’s degree or higher 283 58.4 62.5 59.0 57.0 58.3 54.9 58.8
Annual Household Income (thousand USD)
<25 109 24.6 28.7 33.3 19.0 25.0 19.5 22.5
25-59.9 181 40.0 40.0 32.1 41.8 39.3 47.6 38.8
>60 165 35.4 31.3 34.6 39.2 35.7 32.9 38.8
Region
Northeast 76 16.4 18.8 12.8 19.0 14.3 13.4 20.0
Midwest 90 20.5 20.0 25.6 26.6 20.2 18.3 12.5
South 172 37.5 37.5 33.3 29.1 46.4 41.5 36.3
West 117 25.7 23.8 28.2 25.3 19.0 26.8 31.3
Note: No significant differences were found between conditions on participant characteristics.
Table 2 Mean (SD) levels of perceived harm, positive








Moist snuff 7.13 (2.59) 1.72 (1.50) 1.08 (0.57)
Snus 7.35 (2.13) 1.88 (1.62) 1.08 (0.50)
E-cigarettes 4.91 (2.82) 3.47 (2.59) 1.34 (1.20)
Note: All measures were on 1–9 scales with higher scores indicating greater
perceived harm, more positive attitudes, and greater openness to using
the product.
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The GLM analyses on the effects of warning labels on
changes in perceived harm for different tobacco prod-
ucts revealed significant time by group interactions for
moist snuff (F(5, 473) = 2.54, p < .05) and e-cigarettes
(F(5, 474) = 3.38, p < .01). There was no significant time
by group interaction for snus (F(5, 471) = 0.49, p = .78).
Table 3 presents the differences in perceived harm
from pretest to posttest. Seeing the advertisements with
the current warning label increased perceived harm of e-
cigarettes (d = 24). Exposure to graphic warning labels
increased perceived harm of moist snuff (d = 0.27) and
Table 3 Effect of different warning labels and endorsements on perceived harm of tobacco products
Moist snuff Snus E-cigarettes
Pretest Posttest d Pretest Posttest d Pretest Posttest d
Current WL 7.08 7.26 0.10 7.29 7.16 −0.09 5.51 5.96 0.24*
Graphic WL 6.86 7.57 0.27* 7.54 7.56 0.01 4.33 5.67 0.54*
“Lower risks” 7.47 6.96 −0.24* 7.13 6.89 −0.12 4.81 5.15 0.15
“FDA Approved” 7.30 7.45 0.07 7.44 6.98 −0.25* 5.15 5.24 0.04
No Label 7.26 7.59 0.13 7.32 7.20 −0.05 5.08 5.20 0.05
Control Advertisement 6.78 7.31 0.20 7.37 7.27 −0.04 4.56 4.94 0.19
*p < .05 (Significant differences from pretest to posttest, multivariate simple effects of time based on the linearly independent pairwise comparisons among the
estimated marginal means).
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“lower risk” label significantly lowered perceived harm of
moist snuff (d = −0.24) and the “FDA Approved” label de-
creased perceived risk of snus (d = −0.25). The changes in
perceived harm are represented graphically in Figure 2.
Effect of warning labels on changes in positive attitudes
towards alternative tobacco products
The GLM analyses for the effects of various labels on
changes in positive attitudes towards alternative tobacco
products showed no significant time by condition interac-
tions for all three products: moist snuff (F(5, 465) = .402,
p = .85), snus (F(5, 464) = .285, p = .92), and e-cigarettes
(F(5, 467) = .736, p = .58).
For specific conditions (Table 4), advertisements with
current warning label (d = −0.28) or graphic warning
label (d = −0.26) decreased positive attitudes towards



















  Current Warning Labe
  “Lower risk”
  No Label
Figure 2 Changes in perceived harm from pretest to posttest for cigare
condition. Note: Perceived harm was measured on a 9-point scale, with anEffect of warning labels on changes in openness to trying
alternative tobacco products
For openness to trying alternative tobacco products, there
were no significant time by condition interactions for all three
product: moist snuff (F(5, 462) =1.84, p= .10), snus (F(5, 459)
=1.40, p= .22), and e-cigarettes (F(5, 462) = 1.57, p = .17).
Openness to trying moist snuff went up in every con-
dition (including control) with the exception of “lower
risk” and no label condition where increases were not
statistically significant (Table 5). For snus, openness in-
creased in all but “lower risk” condition. For e-cigarettes,
openness significantly increased in every condition except
the graphic warning label and “FDA-approved” conditions.
Behavioral sample selection
Overall, 14.9% (71) of participants were interested in receiv-
ing a free sample of alternative tobacco products, specific-
ally, moist snuff (5.5%), snus (7.5%), and e-cigarettes (13.9%).posttest pretest posttest
nus E-cigarettes
l   Graphic Warning Label
  “FDA Approved”
  Control Ad
ttes, snus, electronic cigarettes and moist snuff by warning label
swers ranging from 1 – Not at all harmful to 9 – Extremely harmful.
Table 4 Effect of different warning labels and endorsements on positive attitudes towards alternative tobacco
products
Moist snuff Snus E-cigarettes
Pretest Posttest d Pretest Posttest d Pretest Posttest d
Current WL 1.90 1.88 −0.02 1.93 2.02 0.07 3.06 2.67 −0.28*
Graphic WL 1.77 1.74 −0.03 1.84 1.85 0.00 3.48 3.02 −0.26*
“Lower risks” 1.76 1.72 −0.04 2.05 2.03 −0.03 3.68 3.56 −0.09
“FDA Approved” 1.75 1.60 −0.18 1.87 2.04 0.12 3.44 3.14 −0.20
No Label 1.45 1.51 0.09 1.72 1.76 0.03 3.39 3.11 −0.15
Control Advertisement 1.67 1.69 0.01 1.88 1.83 −0.03 3.78 3.69 −0.07
*p < .05 (Significant differences from pretest to posttest, multivariate simple effects of time based on the linearly independent pairwise comparisons among the
estimated marginal means).
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the proportion of people interested in a free sample (χ2(5) =
1.95, p = .85). People who were interested in receiving a free
sample of alternative tobacco products had significantly
lower perceptions of harm of corresponding tobacco prod-
ucts (measured at posttest) than those not interested in a
free sample. Specifically, those interested in a free sample of
moist snuff (Mint) had lower perceived harm of moist snuff
(Mint = 6.4) compared to those not interested (Mnot = 7.4; t
(472) = 2.37, p < .05), for snus, Mint = 6.1 vs. Mnot = 7.2
(t(463) = 2.74, p < .01), and for e-cigarettes Mint = 3.8
vs. Mnot = 5.6 (t(97.3) = 5.79, p < .001). Unequal vari-
ance t-tests were used for e-cigarettes [32].
Recall of warning labels
Correct recall of warning label differed by condition (χ2
(5) = 33.48, p < .001), the highest recall being in “lower
risks” (83.5%) and graphic warning label (80.2%) condi-
tions, followed by control (correct recall of no warning
label, 78.7%), then by current warning label (75.3%),
“FDA Approved” (64.3%), and no warning label (47.1%).
Only 2.5% of participants indicated seeing labels that
were not used in the study.
Discussion
To our knowledge, this research is the first to examine
effects of an “FDA Approved” label and “lower risk” labelTable 5 Effect of different warning labels and endorsements
Moist snuff
Pretest Posttest d Pret
Current WL 1.12 1.88 0.38* 1.0
Graphic WL 1.00 1.44 0.33* 1.0
“Lower risks” 1.12 1.31 0.19 1.1
“FDA Approved” 1.07 1.33 0.29* 1.1
No Label 1.10 1.35 0.20 1.0
Control Advertisement 1.07 1.48 0.30* 1.0
*p < .05 (Significant differences from pretest to posttest, multivariate simple effects
estimated marginal means).for alternative tobacco products. Seeing advertisements
with “FDA Approved” label significantly decreased per-
ceived harm of snus among non-users of tobacco. Seeing
advertisements with a “lower risk” warning label pro-
posed by the R.J. Reynolds tobacco company (“Warning:
No tobacco product is safe, but this product presents
substantially lower risks to health than cigarettes”) sig-
nificantly decreased perceived harm of moist snuff, the
traditional smokeless tobacco product. This suggests
that the endorsement label suggested by R.J. Reynolds
may function similarly to the “FDA Approved” label,
which is prohibited, decreasing perceived harm of to-
bacco products. Research using previously secret in-
ternal tobacco industry documents revealed that some
tobacco companies have supported governmental regula-
tion of tobacco as a strategy to improve their public
image [33]. In doing so, tobacco companies framed to-
bacco use as an individual choice and portrayed them-
selves as responsible manufacturers of risky products
[34]. The fact that the new warning label for smokeless
tobacco proposed by R. J. Reynolds lowered perceptions
of harm of moist snuff among non-users of tobacco indi-
cates that this warning label applied to traditional
smokeless tobacco (which has a relatively high level of
perceived harm to begin with) can significantly lower
perceptions of harm. Some argue that depicting smoke-
less and alternative tobacco products as less harmfulon openness to trying alternative tobacco products
Snus E-cigarettes
est Posttest d Pretest Posttest d
8 1.75 0.39* 1.12 1.72 0.37*
3 1.34 0.29* 1.54 1.70 0.09
4 1.33 0.18 1.40 2.18 0.38*
5 1.47 0.26* 1.40 1.62 0.14
5 1.55 0.36* 1.15 1.71 0.42*
5 1.33 0.24* 1.42 1.85 0.24*
of time based on the linearly independent pairwise comparisons among the
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to switch to less dangerous tobacco products and avoid
the worst health consequences of cigarette smoking
[35,36]. However, endorsing alternative tobacco products
as less harmful might encourage initiation in youth or
non-users, relapse in former smokers, or deter smokers
from quitting, thus increasing harm to public health
[37]. This study demonstrates that the “lower risk” warn-
ing label also leads to perceptions of lower risk among
non-tobacco users. Even though participants in this
study were non-smokers and non-users of smokeless to-
bacco, over 4% had tried one of the alternative tobacco
products, most frequently e-cigarettes. Our data show
that at least some non-smokers are trying and using
e-cigarettes, and that interest in trying the products
was higher among those non-users of tobacco who
had lower perception of harm of these products. This
study provides additional evidence suggesting the FDA
should deny the R.J. Reynolds’s petition to replace the
current warning label with a warning label communicating
lower risk of smokeless tobacco.
This is also the first study to investigate the effects of
warning labels on perceptions of electronic cigarettes.
Placing current warning label used on smokeless tobacco
(“Warning: This product is not a safe alternative to ciga-
rettes”) or a graphic warning label on e-cigarette advertise-
ments significantly increased perceived harm of e-cigarettes
among non-users of tobacco products. It should be noted
that perceived harm of e-cigarettes increased in all condi-
tions (although not significantly) with the exception of
when participants saw an e-cigarette advertisement without
a warning label. In early 2014, the FDA proposed a “deem-
ing rule” [38], extending its regulatory authority to other
tobacco products, including electronic cigarettes. One
of the provisions of this rule is to add the warning
label to electronic cigarettes, “WARNING: This prod-
uct contains nicotine derived from tobacco. Nicotine is
an addictive chemical”. (If the product contains no
nicotine, the proposed warning label would state, ‘This
product is derived from tobacco”). Based on our find-
ings, it is likely that any warning label on electronic
cigarettes would increase perceptions of risk among
non-users of tobacco, and, as such, would be helpful in
reducing population-level harm by reducing interest in
the use of the products among non-users of tobacco.
Given the current lack of evidence about the long-
term health effects of e-cigarettes, warning labels could
also communicate the uncertainty about health effects of
e-cigarettes; future studies should examine the effects of
these types of warning labels on perceived harm.
It is worth noting that although participants were non-
users of tobacco (who had not smoked more than 100
cigarettes or used smokeless tobacco more than 20 times
in their lifetime), almost 9% reported trying alternativetobacco products and over 4% were current (past 30 days)
users (those current users were excluded from the study).
E-cigarettes were used the most frequently with 5.3%
reporting ever use and 3.4% reporting past month use,
followed by snus (ever use 2.8%, past 30 days 1.0%)
and moist snuff (ever use 2.6%, past 30 days 1.4%).
These e-cigarette trial numbers are higher than those
reported previously. In 2010, 0.8% of never-smokers
ever tried and 0.3% reported past month use of e-cigarettes
[39]; another report indicated 1.2% ever use among never
smokers [40]. It appears that as electronic cigarettes are be-
coming more visible in the society, more non-smokers may
be trying and using them.
We also examined effects of warning labels on atti-
tudes and behavioral intentions and found little effect of
specific warning labels on those variables. The only sig-
nificant change across all conditions and all three prod-
ucts was that participants who saw either the current
warning label or the graphic warning label significantly
decreased positive attitudes towards e-cigarettes. These
significant changes occurred in the same conditions that
exhibited significant increase in perceived harm of e-
cigarettes, suggesting that increase in perceived harm
could possibly be responsible for decrease in positive at-
titudes towards e-cigarettes.
Openness to trying alternative tobacco products in-
creased from pretest to posttest across every condition (sig-
nificantly in over half the conditions) for all three products.
Because the openness increased in every condition, even in
control conditions where participants did not see advertise-
ments for tobacco products, it is likely that this increase is
an effect of a repeated testing. This finding is in line with a
previous study (with a nationally representative sample of
smokers) where openness to trying snus increased across
all conditions [31]. It should also be noted that even with a
slight increase in openness, participants predominantly
remained “not at all open” at posttest, because the initial
openness was so low, with most participants selecting the
lowest possible option on the openness scale.
Although we did not measure actual behavior (e.g., to-
bacco use) in this study, we asked participants to select
a free sample of the product and 14.9% of participants
were interested in a free sample. There was no differ-
ence across the warning labels conditions, but overall,
non-users of tobacco who wished to receive a free
sample of alternative tobacco product held signifi-
cantly lower perceptions of harm of these products
than those who opted out of receiving free samples.
Thus, perceived harm is related to potential behavior
(trying the product), the finding that is in line with
past research [10].
Recall for warning labels was different across the con-
ditions, with highest recall for graphic warning labels. It
should be noted that recall was only measured for the
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textual warnings rather than indicate that they saw a graphic
warning label. If we asked whether participant saw a graphic
warning label, the recall might have been even higher. Low
recall of “FDA Approved” label could be explained by the
fact that people do not perceive it as ‘warning.’
Limitations of this study include that it was a non-
probability-based sample; however, the sample was drawn
from a diverse sample of non-users of tobacco in the
United States with heterogeneous demographics. Our
sample was more educated (with 58% of participants being
college educated) as compared to the educational levels
reported by the US census (29% of adult population in
general, including tobacco users and non-users, being
college educated) [41] and the 2012 NHIS (31% of
non-smokers being college-educated) [42]. Although
we did have a sizable proportion of lower educated
participants and education was not related to our main
outcome variables, the characteristics of the sample might
suggest the study results may limit the generalizability of
the study to more educated populations.
Self-reported measures of perceived harm, attitudes,
and openness to trying tobacco products might have
been subject to social desirability bias, resulting in the
high ratings of perceived harm and low attitudes and
openness levels that we observed in this study, under-
estimating the effects of “lower risk” and “FDA Ap-
proved” labels. While the increase in perceived harm of
alternative tobacco products was unambiguous for the
current and graphic warning labels, the “lower risk” and
“FDA Approved” label conditions showed weaker effects,
so larger samples may be needed to obtain stable and
more conclusive estimates of these smaller effects. Fu-
ture studies should take these issues into account.
Conclusions
In conclusion, this study provides the first evidence
against allowing “reduced harm” or “lower risk” labels
on alternative tobacco products. While further data
should be collected to validate our results, our findings
provide initial evidence that endorsements such as the
one proposed by RJ Reynolds may have similar effects to
the prohibited “FDA Approved” label. Warning labels
may be an effective way to decrease interest in e-cigarettes
among non-users of tobacco. Regulatory agencies should
consider implementing graphic warning labels for smokeless
tobacco and investigate use of warning labels for e-cigarettes.
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